We are lowering our fair value estimate for Vertex (VRTX) to $130 per share from $136 following the company’s announcement of lower-than-expected 2017 guidance for Kalydeco and Orkambi sales. We expect European reimbursement for Orkambi to remain slow-going, while the side effect profile of the drug tempers our outlook for a speedy sales ramp-up in the U.S. Management now expects Kalydeco sales in the range of $690 million-$710 million and Orkambi sales at $1.1 billion-$1.3 billion in the upcoming year. We project Kalydeco and Orkambi sales in the top range of the company’s guidance, which are roughly 5% and 25% haircuts to our original 2017 sales projections for the two drugs, respectively. Despite our lowered fair value estimate, Vertex shares look undervalued in our view. We believe the market is underestimating Vertex’s entrenched position in the cystic fibrosis market supported by a robust pipeline of next-generation products.
Orkambi headwinds are expected to weigh on the company’s near-term growth. However, we believe the successful launch of next-generation corrector tezacaftor (VX-661) in combination with potentiator drug Kalydeco would boost penetration into the patient population with two F508del mutations and provide an opportunity to serve patients with one F508del mutation and residual CFTR protein functionality in 2018. The company expects to submit an NDA in the second half of the year if phase III trials meet their endpoints (data expected 1H 2017). The tezacaftor combination is not expected to produce the bronchoconstriction seen in Orkambi, which is encouraging and could translate into lower discontinuation rates and higher uptake in the cystic fibrosis market.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.
Kelsey Tsai, CFA does not own shares in any of the securities mentioned above. Find out about Morningstar's editorial policies.